1.64
price up icon0.00%   0.00
after-market Handel nachbörslich: 1.73 0.09 +5.49%
loading
Schlusskurs vom Vortag:
$1.64
Offen:
$1.51
24-Stunden-Volumen:
27,423
Relative Volume:
0.40
Marktkapitalisierung:
$77.26M
Einnahmen:
$18.11M
Nettoeinkommen (Verlust:
$-18.95M
KGV:
-3.7486
EPS:
-0.4375
Netto-Cashflow:
-
1W Leistung:
-1.50%
1M Leistung:
-20.00%
6M Leistung:
-27.75%
1J Leistung:
-43.45%
1-Tages-Spanne:
Value
$1.50
$1.7566
1-Wochen-Bereich:
Value
$1.325
$1.87
52-Wochen-Spanne:
Value
$1.325
$3.5807

Adagene Inc Adr Stock (ADAG) Company Profile

Name
Firmenname
Adagene Inc Adr
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
138
Name
Twitter
Name
Nächster Verdiensttermin
2024-03-28
Name
Neueste SEC-Einreichungen
Name
ADAG's Discussions on Twitter

Vergleichen Sie ADAG mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ADAG
Adagene Inc Adr
1.64 77.26M 18.11M -18.95M 0 -0.4375
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.01 124.29B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.64 68.39B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
590.06 35.99B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
262.16 33.93B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
264.32 28.47B 3.81B -644.79M -669.77M -6.24

Adagene Inc Adr Stock (ADAG) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-01-31 Herabstufung Morgan Stanley Overweight → Equal-Weight
2021-06-25 Eingeleitet China Renaissance Buy
2021-03-08 Eingeleitet Goldman Buy
2021-03-08 Eingeleitet Jefferies Buy
2021-03-08 Eingeleitet Morgan Stanley Overweight

Adagene Inc Adr Aktie (ADAG) Neueste Nachrichten

pulisher
Mar 27, 2025

Adagene stock hits 52-week low at $1.62 amid market challenges By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

Adagene stock hits 52-week low at $1.62 amid market challenges - Investing.com

Mar 27, 2025
pulisher
Mar 25, 2025

Adagene (ADAG) to Release Quarterly Earnings on Thursday - Defense World

Mar 25, 2025
pulisher
Mar 24, 2025

Adagene Reports 33% Overall Response Rate in Phase 2 Expansion of Muzastotug for MSS CRC, Highlights Financial Position and Future Milestones - Nasdaq

Mar 24, 2025
pulisher
Mar 24, 2025

Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Mar 24, 2025
pulisher
Mar 24, 2025

Adagene Reveals Breakthrough Cancer Trial Results in 2024 Financial Update - Stock Titan

Mar 24, 2025
pulisher
Mar 14, 2025

Adagene Inc. (NASDAQ:ADAG) Short Interest Down 55.9% in February - Defense World

Mar 14, 2025
pulisher
Mar 13, 2025

Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit - GlobeNewswire

Mar 13, 2025
pulisher
Mar 13, 2025

Adagene Inc. to Present ADG126 SAFEbody® Data at 11th Annual Immuno-Oncology 360⁰ Summit in Boston - Nasdaq

Mar 13, 2025
pulisher
Mar 13, 2025

Adagene's Revolutionary Cancer Treatment Targets CTLA-4: Key Presentation Coming to IO360 Summit - StockTitan

Mar 13, 2025
pulisher
Mar 12, 2025

Adagene to Present at the Leerink Partners Global Biopharma Conference 2024, Business Wires News - AsiaOne

Mar 12, 2025
pulisher
Mar 07, 2025

Adagene Announces Participation At Leerink’s Global Healthcare Conference 2025 - BERNAMA

Mar 07, 2025
pulisher
Mar 07, 2025

Adagene to Present at Leerink’s Global Healthcare Conference 2025 - GlobeNewswire

Mar 07, 2025
pulisher
Mar 06, 2025

Adagene to Present at Leerink's Global Healthcare Conference 2025 - The Manila Times

Mar 06, 2025
pulisher
Mar 06, 2025

Can Adagene's CEO Reveal New Strategic Plans at Upcoming Leerink Conference? - StockTitan

Mar 06, 2025
pulisher
Feb 27, 2025

Adagene Inc. to Initiate Phase 2 Trial of ADG126 for Colorectal Cancer with Enrollment Starting in April 2025 - Nasdaq

Feb 27, 2025
pulisher
Feb 27, 2025

Adagene Announces Investigator Initiated Phase 2 Trial for Neoadjuvant Muzastotug (ADG126) in Colorectal Cancer - GlobeNewswire

Feb 27, 2025
pulisher
Feb 27, 2025

Could This New Colorectal Cancer Trial Change Pre-Surgery Treatment? Adagene Tests ADG126 - StockTitan

Feb 27, 2025
pulisher
Feb 23, 2025

Head to Head Analysis: Rafael (NYSE:RFL) versus Adagene (NASDAQ:ADAG) - Defense World

Feb 23, 2025
pulisher
Feb 16, 2025

Short Interest in Adagene Inc. (NASDAQ:ADAG) Declines By 50.2% - MarketBeat

Feb 16, 2025
pulisher
Feb 13, 2025

Adagene Inc. (NASDAQ:ADAG) Short Interest Update - Defense World

Feb 13, 2025
pulisher
Feb 13, 2025

Head to Head Survey: Adagene (NASDAQ:ADAG) and Corvus Pharmaceuticals (NASDAQ:CRVS) - Defense World

Feb 13, 2025
pulisher
Feb 04, 2025

Morgan Stanley Downgrades Adagene (NASDAQ:ADAG) to Equal Weight - MarketBeat

Feb 04, 2025
pulisher
Feb 04, 2025

Adagene Inc. (NASDAQ:ADAG) Sees Large Increase in Short Interest - MarketBeat

Feb 04, 2025
pulisher
Feb 03, 2025

Adagene (NASDAQ:ADAG) Cut to “Equal Weight” at Morgan Stanley - Defense World

Feb 03, 2025
pulisher
Feb 01, 2025

FY2024 Earnings Estimate for Adagene Issued By HC Wainwright - MarketBeat

Feb 01, 2025
pulisher
Jan 31, 2025

HC Wainwright Estimates Adagene FY2029 Earnings - MarketBeat

Jan 31, 2025
pulisher
Jan 31, 2025

Morgan Stanley Downgrades Adagene to Equal Weight From Overweight -January 31, 2025 at 07:57 am EST - Marketscreener.com

Jan 31, 2025
pulisher
Jan 31, 2025

Adagene Inc. (NASDAQ:ADAG) Sees Significant Growth in Short Interest - Defense World

Jan 31, 2025
pulisher
Jan 30, 2025

Adagene Reports Promising Results in Colorectal Cancer Study - TipRanks

Jan 30, 2025
pulisher
Jan 29, 2025

FY2029 Earnings Forecast for Adagene Issued By HC Wainwright - Defense World

Jan 29, 2025
pulisher
Jan 28, 2025

Adagene Announces Updated Data from Phase 1b/2 Study of - GlobeNewswire

Jan 28, 2025
pulisher
Jan 27, 2025

Adagene (NASDAQ:ADAG) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat

Jan 27, 2025
pulisher
Jan 27, 2025

H.C. Wainwright lifts Adagene stock target to $8 on ASCO data - Investing.com

Jan 27, 2025
pulisher
Jan 27, 2025

Adagene reports positive colorectal cancer trial results - Investing.com India

Jan 27, 2025
pulisher
Jan 27, 2025

ADAGAdagene Inc. American Depositary Shares Latest Stock News & Market Updates - StockTitan

Jan 27, 2025
pulisher
Jan 27, 2025

Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium - The Manila Times

Jan 27, 2025
pulisher
Jan 27, 2025

Adagene's Muzastotug Shows 33% Response Rate in Colorectal Cancer Trial - StockTitan

Jan 27, 2025
pulisher
Jan 22, 2025

Adagene to present new ADG126 clinical data at ASCO-GI - MSN

Jan 22, 2025
pulisher
Jan 22, 2025

Adagene to present new ADG126 clinical data at ASCO-GI By Investing.com - Investing.com Australia

Jan 22, 2025
pulisher
Jan 22, 2025

Adagene to Announce Updated Data from Phase 1b/2 Study of - GlobeNewswire

Jan 22, 2025

Finanzdaten der Adagene Inc Adr-Aktie (ADAG)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$67.48
price down icon 1.23%
$73.33
price down icon 0.15%
$31.79
price up icon 1.63%
$18.91
price down icon 7.58%
$92.01
price down icon 1.40%
biotechnology ONC
$264.32
price down icon 3.81%
Kapitalisierung:     |  Volumen (24h):